NCT06815549View on ClinicalTrials.gov

"An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
P. AeruginosaBaumanniiKlebsiella PneumoniaE.coli InfectionsEnterococcus Faecalis InfectionChronic Bacterial Cystitis
Interventions
DRUG

Fluorothiazinone, tablets 300 mg

patients will receive Fluorothiazinone, tablets 300 mg at a dose 1200 mg/day (2 tablets twice a day) for 14 days

DRUG

Nitrofurantoin 100 MG

Comparison arm patients will receive Nitrofurantoin in accordance with the instructions for medical use.

All Listed Sponsors
lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER